The First In Vivo CRISPR Therapy to Win a Phase 3 Trial, and the $1.9B Acquisition Made Two Days Later – This Week in Biotech #98
Intellia's hereditary angioedema result validates in vivo gene editing, Sun Pharma makes the biggest biopharma deal of 2026, and the FDA draws a new line in breast cancer (Apr 24-30, 2026).
Welcome back to This Week in Biotech by Biotech Blueprint, edition 98, covering biotech and biopharma news from April 24th to 30th, 2026.
🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.
🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.
👥 If you haven’t already, please connect with me or follow me on LinkedIn.
VIDEO SUMMARY
THIS WEEK’S KEY TAKEAWAYS 🔑
This week’s defining clinical event came on April 27, when Intellia Therapeutics reported that a single dose of lonvoctocogene-z, an in vivo CRISPR therapy, reduced hereditary angioedema attack rate by 87% versus placebo in Phase 3, with 62% of recipients attack-free or off other prophylactic therapy compared to 11% on placebo. This is the first Phase 3 win for any in vivo CRISPR therapy, and it matters because in vivo gene editing has faced persistent questions about whether it could deliver durable, tolerable results in a chronic non-cancer indication at the registration level. This trial answered that. Rolling regulatory submission has started, with a US launch targeted for the first half of 2027.
Two days later, Italy’s Chiesi agreed to acquire KalVista Pharmaceuticals for $1.9 billion for Ekterly, an oral on-demand hereditary angioedema rescue therapy barely nine months into commercial launch. Ekterly is rescue treatment. Lonvoctocogene-z is one shot prophylaxis. They serve different moments in disease management, but the long run question is whether a patient population that can functionally eliminate attacks with a single CRISPR dose will keep reaching for a rescue pill at the same rate. Chiesi paid a rare disease premium two days after the prophylaxis ceiling moved. Whether that was disciplined portfolio building or a misjudgment of modality risk, the market will render a verdict over the next few years.
The week’s M&A story was Sun Pharma’s $11.75 billion acquisition of Organon, the largest biopharma deal of 2026. Organon was spun out of Merck in 2021 with established brands and biosimilars, and Sun is buying scale in mature markets and manufacturing depth. The deal signals that Indian generics and emerging market specialty pharma are now serious players in large cap consolidation, and Section 232 tariff dynamics that disadvantage import-dependent biosimilar manufacturers may have added urgency to building US-domiciled scale.
On the regulatory side, the FDA’s advisory committee voted 6 to 3 against the clinical benefit of AstraZeneca’s camizestrant in a circulating tumor DNA-triggered first-line breast cancer switch setting, the agency’s first such meeting in nine months. The progression-free survival data was strong, a hazard ratio of roughly 0.44. The committee said no anyway, citing immature overall survival, confounded secondary endpoints, and a safety profile that’s hard to justify in a clinically stable population. The precedent is important: a compelling progression-free survival signal triggered by a liquid biopsy biomarker alone is not sufficient to move stable patients to a new therapy.
Earnings closed the week with Lilly posting $19.8 billion in first quarter revenue, up 56% year-over-year, with Mounjaro and Zepbound combining for $12.76 billion. Guidance was raised to $82 to $85 billion for the full year. Foundayo’s early launch data was mixed. 3,707 prescriptions in week two versus roughly 18k for oral Wegovy at the same stage, though Lilly noted 20k patients already on the drug by the earnings call. Volume growth across the franchise is more than offsetting pricing concessions, and the obesity narrative remains intact heading into ASCO season.
BIOTECH/PHARMA NEWS 🧬
🔹 Intellia Therapeutics reported that a single dose of lonvoctocogene-z, an in vivo CRISPR therapy, reduced hereditary angioedema attack rate by 87% versus placebo in Phase 3, with 62% of recipients attack-free or off other prophylactic therapy compared to 11% on placebo. Safety was clean, with no serious treatment-related adverse events in the topline. This is the first Phase 3 win for any in vivo CRISPR therapy, and it matters because in vivo gene editing, where the editing happens inside the body rather than in a lab dish, has faced persistent questions about whether it could deliver durable, tolerable results in a chronic non-cancer indication at the registration level. This trial, with a proper placebo control and a clean safety readout, is the clearest answer yet. Rolling regulatory submission has started, with a US launch targeted for the first half of 2027.
🔹 Italy’s Chiesi agreed to acquire KalVista Pharmaceuticals for $27 per share in cash, roughly $1.9B and a 36% premium to KalVista’s 30 day average price. KalVista’s only marketed asset is Ekterly, an oral on-demand plasma kallikrein inhibitor approved in July 2025 for hereditary angioedema attacks, barely nine months into commercial launch. The timing is uncomfortable. Ekterly is rescue therapy. Lonvoctocogene-z is one shot prophylaxis. They serve different moments in disease management, but if patients can functionally eliminate attacks with a single CRISPR dose, the lon run volume outlook for rescue therapy gets harder to underwrite. Chiesi paid the rare disease premium two days after the prophylaxis ceiling moved. That timing will be debated for a while.
🔹 The FDA’s Oncologic Drugs Advisory Committee voted 6 to 3 on April 30 against the clinical benefit of AstraZeneca’s camizestrant in a specific first-line breast cancer setting, the agency’s first such meeting in 9 months. The SERENA-6 trial randomized patients who developed an ESR1 mutation during first-line hormone therapy plus a CDK4/6 inhibitor to either switch to camizestrant or stay on their current regimen. Progression free survival was 16.0 to 16.6 months on camizestrant versus 9.2 months on continued therapy, a hazard ratio of roughly 0.44, which is a large effect. The committee wasn’t convinced: secondary endpoints were confounded by protocol-mandated switching, overall survival is immature, and a safety profile including neutropenia, visual disturbances, and a potential cardiac signal with ribociclib is hard to justify in a clinically stable population. The vote is non-binding, but the message is that a strong progression-free survival signal triggered by a circulating tumor DNA biomarker alone is not enough to move stable patients to a new therapy.
🔹 Sun Pharma signed a definitive agreement to acquire Organon for $14 per share in cash, an enterprise value of $11.75B, the largest biopharma deal of 2026. Organon was spun out of Merck in 2021 with a portfolio of established brands and biosimilars. The combined company would have pro forma revenue of roughly $12.4B. This is about scale in established markets and a deeper biosimilars manufacturing base, and it signals that Indian generics and emerging market specialty pharma companies are now serious players in large cap consolidation in a way that Western companies have largely sat out. Section 232 tariff dynamics, which structurally disadvantage import-dependent biosimilar manufacturers, may have added strategic urgency to building US-domiciled scale.
🔹 Teva agreed to acquire Emalex Biosciences for $700M upfront plus up to $200M in milestones for ecopipam, a first in class dopamine D1 receptor antagonist that hit its Phase 3 primary endpoint in pediatric Tourette syndrome, with an NDA filing planned for the second half of 2026. Existing Tourette treatments carry significant tolerability burden in kids, largely through D2-mediated metabolic effects. A selective D1 mechanism that sidesteps that is genuinely differentiated, if the safety holds in broader use. The deal fits Teva’s ongoing effort to build a credible branded neuroscience franchise alongside its legacy generics business.
🔹 Eli Lilly reported Q1 revenue of $19.8B, up 56% year-over-year, with adjusted earnings per share of $8.55 versus consensus of $6.66. Mounjaro and Zepbound combined for $12.76B in the quarter, and Lilly raised full year revenue guidance to $82 to $85B. Foundayo, the oral GLP-1 launched April 1, wasn’t broken out separately, but launch data told a nuanced story: early IQVIA prescription tracking showed 3,707 scripts in week two, roughly five times fewer than oral Wegovy at the same stage, sending shares lower. Lilly pushed back on the earnings call, noting 20k patients were already on the drug and that around 8k prescribers had written Foundayo scripts, roughly a third of whom had never written an oral GLP-1 before. The broader earnings verdict is that GLP-1 pricing concerns haven’t materially dented the franchise. Volume growth is more than offsetting any pricing concession.
🔹 Boehringer Ingelheim reported Phase 3 results for survodutide, a once-weekly injectable glucagon/GLP-1 dual agonist licensed from Zealand Pharma, showing 16.6% weight loss versus 3.2% on placebo at 76 weeks in people with obesity or overweight without type 2 diabetes. The headline number is solid, though the topline release leaves tolerability questions open. Discontinuation rates hit 24.6% in Phase 2, and Phase 3 didn’t clearly address whether that improved. Full data will be presented at the American Diabetes Association meeting in June. No filing timeline has been announced, but Boehringer is positioning survodutide as a potential first dual GLP-1/glucagon agonist to reach the market.
🔹 The FDA launched a real time clinical trials initiative with AstraZeneca and Amgen as initial partners, targeting 20 to 40% reductions in trial timelines by receiving endpoint and safety data continuously rather than at completion. A request for information is open through May 29. Worth watching, but the operational burden of real-time reporting will favor larger sponsors with sophisticated data infrastructure over most mid-cap biotechs.
WATCHLIST 👀
Viridian Therapeutics REVEAL-2 (elegrobart, chronic thyroid eye disease): Phase 3 topline expected Q2 2026; possibly May
Novo Nordisk Q1 2026 earnings - May 6: first commentary on competitive response to Foundayo and Mounjaro/Zepbound
Vertex Q1 2026 earnings - May 4: Casgevy uptake and Alyftrek commentary
Pfizer Q1 2026 earnings - May 5: Comirnaty and Paxlovid trajectory plus Vyndamax franchise commentary post-settlement
Catalyst Pharmaceuticals (CPRX) Q1 earnings - May 11: possible Angelini bid commentary
Merck IDVYNSO HIV launch - May 11: first week prescription read versus Biktarvy switch volumes
Seaport Therapeutics IPO pricing: terms set at $16-$18 for $201M raise; pricing expected this week
Hemab Therapeutics IPO pricing: terms set targeting $200M at $715M market cap
ASCO 2026, May 29-June 2, Chicago: plenary session features Revolution daraxonrasib LBA5 (May 31) plus IDEAYA darovasertib LBA. Five plenary abstracts confirmed: PROTEUS, SARC041, LIBRETTO-432, HARMONi-6, and RASolute 302
Have a great rest of your week and thanks for reading Biotech Blueprint!
DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Cover image credit: iStock, avgust01
This is a useful newsletter